Advertisement

Topics

FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma

15:37 EDT 12 Jul 2019 | OncLive

A supplemental biologics license application has been submitted to the FDA for a new subcutaneous formulation of daratumumab (Darzalex) for the treatment of patients with multiple myeloma.

Original Article: FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma

NEXT ARTICLE

More From BioPortfolio on "FDA Approval Sought for Subcutaneous Daratumumab in Multiple Myeloma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...